Pralnacasan

DB04875ExperimentalSmall molecule

Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).

Mechanism: Pralnacasan inhibits interleukin-1beta converting enzyme (ICE), an enzyme that regulates the production of IL-1 and IFN gamma - intercellular mediators that initiate and sustain the process of inflammation. Inhibiting ICE may be an effective strategy for curtailing damaging inflammatory processes common to a number of acute and chronic conditions, such as rheumatoid arthritis (RA) and osteoarthritis.
Curator reviewed
Primary indication: For the treatment of rheumatoid arthritis (RA).Curator reviewed
Formula / weight: C₂₆H₂₉N₅O₇ · 523.5378 g/mol (avg)
Code names: HMR-3480 · HMR-3480/VX-740 · VX-740

Resolves to

Compound

Structure

InChIKeyCXAGHAZMQSCAKJ-WAHHBDPQSA-NSMILESCCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN2N1C(=O)[C@H](CCC2=O)NC(=O)C1=NC=CC2=CC=CC=C12

Targets

What you can answer from here — as of March 06, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

558Drug interactionsStructured to mechanism, not free text

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pralnacasan, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.